Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 31, 2024Open Access

A Seamless Phase II/III Design with Dose Optimization for Oncology Drug Development

View Full Paper
Ask AI
Bookmark
Share

Authors

YLYuhan LiBrigham and Women's HospitalYZYiding ZhangSanofi (United States)GMGu MiSanofi (France)

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Li et al. (2024) studied this question.

synapsesocial.com/papers/68e67860b6db643587602c2fhttps://doi.org/10.48550/arxiv.2406.00196
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A seamless phase II/III design with dose optimization for oncology drug development2024 · 8 citations
  2. 2A Seamless Two‐Stage Phase I/ II Trial Design With Backfill and Joint Monitoring for Dose Optimization2026 · 1 citations
  3. 3M-DODII: Bayesian dose optimization design for randomized phase II study with multiple indications2025 · 1 citations
  4. 4Three steps toward dose optimization for oncology dose finding2024 · 8 citations
  5. 5Design Strategy and Consideration for Oncology Dose-Optimization: An Industry Perspective2024 · 3 citations